Physician profile
Alex M Arnouk
NPI 1609295666
$3,088.22
in general payments reported to CMS, 2019-2025
32 companies · $192 in 2025
The $192 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $249 · 2020: $623 · 2021: $1,331 · 2022: $151 · 2023: $358 · 2024: $184 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $417 · Education: $259 · Honoraria: $58.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $416.98 |
| Education | $258.99 |
| Honoraria | $58.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $703.00 | 2019-2025 | Xtandi |
| Janssen Biotech, INC. | $265.59 | 2019-2021 | |
| Dendreon Pharmaceuticals LLC | $229.23 | 2019-2022 | |
| Boston Scientific Corporation | $193.03 | 2019-2025 | Ams 700 |
| Myriad Genetic Laboratories, INC. | $165.56 | 2020-2022 | |
| Myovant Sciences INC. | $138.82 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $116.37 | 2019-2025 | |
| Amgen INC. | $102.83 | 2020-2021 | |
| Laborie Medical Technologies Corp. | $102.16 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Endo Pharmaceuticals INC. | $95.94 | 2020-2021 | |
| Pfizer INC. | $84.99 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $82.76 | 2020-2021 | |
| Ambu INC. | $82.46 | 2020-2023 | |
| Abbvie INC. | $70.64 | 2019-2022 | |
| Axonics, INC. | $62.94 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $62.31 | 2021-2022 | |
| Teleflex LLC | $61.73 | 2021-2025 | Deknatel |
| Merck Sharp & Dohme LLC | $58.27 | 2020-2021 | |
| C. R. Bard, INC. & Subsidiaries | $58.00 | 2024 | |
| Metuchen Pharmaceuticals | $40.90 | 2019-2021 | |
| Urovant Sciences INC | $37.93 | 2021-2022 | |
| Neotract INC. | $37.06 | 2020 | |
| Antares Pharma, INC. | $34.30 | 2019-2025 | Xyosted |
| Sun Pharmaceutical Industries INC. | $30.75 | 2020-2021 | |
| Immunitybio, INC. | $28.49 | 2025 | |
| Ferring Pharmaceuticals INC. | $25.99 | 2025 | Adstiladrin |
| Coloplast Corp | $23.96 | 2019 | |
| Ethicon US, LLC | $23.50 | 2024 | Ethicon |
| 180 Medical, INC. | $22.17 | 2021 | |
| Agiliti Surgical, INC. | $18.50 | 2025 | Sonablate Hifu |
| Tolmar Pharmaceuticals, INC. | $14.65 | 2021 | |
| Palette Life Sciences, INC. | $13.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Arnouk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.